Comparison of Efficacy of Less Invasive Surfactant Treatment Under Nasal CPAP and Nasal IPPV

Comparison of Efficacy of Less Invasive Surfactant Treatment Under Nasal CPAP and Nasal IPPV in Premature Babies: CURLISPAP Study

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04698473

Enrollment

Registered

2021-01-07

Start date

2020-10-01

Completion date

2022-12-01

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome

Keywords

NCPAP, NIPPV, LISA

Brief summary

Non invasive ventilation is important in the care of preterm infants with respiratory failure, and surfactant treatment can be use with non invasive ventilation. However, there is no consensus on the best non-invasive ventilation mode for surfactant treatment in preterm infants. Objective: To compare the effectiveness of nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (CPAP) in preterm infants ≤ 29 week gestational age.

Detailed description

This CURLISPAP study was a multicenter, randomized controlled study at six level III neonatal intensive care units (NICUs) in Turkey. The protocol was approved by the ethics committee of each participating centre and Turkish Ministry of Health, Turkish Medicines and Medical Devices Agency. Non invasive ventilated preterm infants with respiratory distress syndrome and gestational age from 241/7 weeks to 296/7 weeks were enrolled within 6 h of birth. Infants with major congenital malformations, need of mechanical ventiation, need of entubation in delivery room and lack of parental consent were excluded. Enrolled infants will randomize into two study groups (NIPPV group and CPAP group). The short binasal prongs will use as interface. For all the groups, if the fraction of inspired oxygen (FiO2) requirement is persistently higher than 0.30 target SpO2 90-94%. For all groups Surfactant by "LISA" technique and with special catheter (LISAcath, Chiesi Pharmaceutics) of surfactant (Curosurf, Chiesi Pharmaceutics) 200 mg/kg. The primary end-point, need of mechanical ventilation within 72 hours following surfactant treatment, will compared between the groups. Short and long-term neonatal outcomes will also evaluate.

Interventions

OTHERNCPAP

NCPAP infants will be randomized into two different non invasive ventilation groups

OTHERNIPPV

NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

24 Weeks to 29 Weeks

Healthy volunteers

Yes

Inclusion criteria

* Gestational age 24 -29 week * Clinical and radiological diagnosis of RDS * Born in a hospital with a study center * Spontaneous breathing * Within the first 6 hours * Non-invasive ventilation and FiO2 requirement \>0.30 * Parental concent

Exclusion criteria

* Major congenital malformations * Need of mechanical ventiation * Need of entubation in delivery room * Air weak syndrome * No parental concent

Design outcomes

Primary

Measure	Time frame	Description
Treatment failure within 72 hours after randomization 72 hours after randomization	within 72 hours after randomization	Need for invasive mechanical ventilation

Secondary

Measure	Time frame	Description
Rate of bronchopulmonary dysplasia	36 weeks of postmenstrual age ]	defined according to the NICHD definition

Countries

Turkey (Türkiye)

Contacts

STUDY_DIRECTORhilal ozkan

Study director

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026